PD98059

Catalog No.S1177

PD98059 Chemical Structure

Molecular Weight(MW): 267.28

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.

Size Price Stock Quantity  
In DMSO USD 134 In stock
USD 147 In stock
USD 470 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 50 Publications

10 Customer Reviews

  • a-c, Inhibitors of BRAFV600E (PLX4032) and MEK1/2 (PD98059 or AZD6244) increase PGC1α and ID2 expression (a, b) and repress integrin expression and signalling (b, c). Cells were treated with indicated concentration of inhibitors for 6 h (a, b) or 24 h (c). d, e, PLX4032 increases the interaction between ID2 and TCF4 (d) and decreases the occupancy of TCF4 at the promoters of integrin genes (e). f–g, PGC1α and ID2 are partially required for PLX4032-mediated inhibition of invasion and metastasis. For in vitro assays (f), A375 cells were incubated with 1 μM PLX4032 for 10 h. Images represent one picture captured per membrane with the scale bar representing 200 μm. Values in a, b, e and f represent mean±s.d. of independent biological triplicates; *P<0.05 and **P<0.01 by Student's t-test  in a, b, e, f.

    Nature, 2016, 537(7620):422-427.. PD98059 purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD98059 purchased from Selleck.

    effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) on SRP72 protein expression was evaluated on Jurkat cells stimulated with rhIL-1. The cells were harvested at 0,120, and 240 min, and the protein expression was verified by WB using antibodies against human SRP72, human SRP54 (nonphosphorylated SRP protein), and humanGAPDHas constitutive protein.Adecreased SRP72 expression at 10 μM and 240 min was found.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  • C, effect of ERK1/2 inhibitor PD98059 (1, 5, and 10 μM) was evaluated in SRP72-immunoprecipitated cell lysates. WB using anti-phosphoserine antibody showed a decreased SRP72 band when used as the inhibitor at concentrations of 1 μM at 240 min, 5 μM at 120 min, and 10 μM at 120 and 240 min (lanes 3, 5, 8, and 9). D, results were analyzed and RUA illustrated, finding significant results at 1 μM at 240 versus 0, 5 μM at 120 versus 0, and 10 μM at 120 versus 0 min.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

    We used real time RT-PCR to investigate the effects of PD98059 on SRP72 mRNA expression. All the samples were treated under the same experimental conditions used in protein tests done by WB, and phosphorylation was measured indirectly by IP-WB. The results did not show significant changes on the mRNA expression of SRP72 after the treatment with these inhibitors.

     

     

    J Biol Chem 2010 285, 32824-32833. PD98059 purchased from Selleck.

  •  

    Activation of a TLR2eERK1/2 pathway in MDDC. (C) MDDC were either untreated or treated with C. pneumoniae alone or in the presence of the ERK1/2 inhibitor PD98059 for 48 h. IL-12p70 and IL-10 release in culture media was assessed by ELISA. (D) MDDC were treated as in panel C for 48 h and then cocultured with purified allogeneic CD3t T cells. On day 12, supernatants were collected, and secreted cytokines were measured by ELISA.

    Microbes Infect 2013 15, 105-14. PD98059 purchased from Selleck.

    HepG2 cells, “Pnt-2” primary HCC cells or THLE-2 normal liver cells were pretreated with PD-98059 (1 mM) or MEK-162 (“MEK”, 1 mM) for 1 h prior toWAY-600 (“WAY”, 100 nM) treatment, after applied period, cell viability and apoptosis were tested by MTT assay (F and H).

    Biochem Biophys Res Commun, 2016, 474(2):330-7.. PD98059 purchased from Selleck.

  • Collagen I and α-SMA are conducive for S. aureus adhesion to and invasion into BMFBs. BMFBs were treated with PD98059 2 h before the addition of 5 ng/ml TGF-β1; 24 h later, the adhesion (A) and invasion (B) assays were performed as previously described. The results are expressed as the mean cfu/ml ± SD from experiments performed in triplicate (*P < 0.05, **P < 0.01).

    Microb Pathog, 2017, 106:25-29. PD98059 purchased from Selleck.

    After starved in serum-free medium for 24h,T47D cells incubated with the indicated concentrations of  PD98059 for 3h,followed by 20-minute  stimolation of 100ng/ml EGF.

     

    2010 Dr. Zhang of Tianjin Medical University. PD98059 purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2.
Features Does not inhibit c-Raf phosphorylated MEK1.
Targets
MEK1 [1]
(Cell-free assay)
2 μM
In vitro

PD98059 inhibits either basal MEK1 or a partially activated MEK produced by mutation of serine at residues 218 and 222 to glutamate (MEK-2E) with IC50 of 2 μM. PD98059 does not inhibit the MAPK homologues JNK and P38. PD98059 is highly selective against MEK, as it does not inhibit a number of other kinase activities including Raf kinase, cAMP-dependent kinase, protein kinase C, v-Src, epidermal growth factor (EGF) receptor kinase, insulin receptor kinase, PDGF receptor kinase, and phosphatidylinositol 3-kinase. PD98059 inhibits PDGF-stimulated activation of MAPK and thymidine incorporation into 3T3 cells with IC50 of ~10 μM and ~7 μM, respectively. [1] PD98059 potently prevents the activation of MEK1 by Raf or MEK kinase with IC50 of 4 μM, and weakly inhibits the activation of MEK2 by Raf with IC50 of 50 μM. PD98059 does not inhibit the activation of MEK homologues MKK4 and RK kinase that participate in stress and interleukin-1-stimulated kinase cascades in KB and PC12 cells, and the activation of p70 S6 kinase by insulin or epidermal growth factor in Swiss 3T3 cells. [2] PD98059 completely blocks the nerve growth factor (NGF)-induced differentiation of PC12 cells without altering cell viability. [3] PD98059 inhibits the proliferation of RAW264.7 cells in the culture containing RANKL in a dose-dependent manner, resulting in an apparent decrease of TRAP-positive cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H1355 NGPOdm1HfW6ldHnvckBCe3OjeR?= M1nRVVI2KM7:TR?= MVexJIg> NFPJc2ZjdHWwdIOgeIhmKEKdYW3QMYlv\HWlZXSgbY5kemWjc3WgbY4heGixc4Doc{1EcGtzIHHu[EBxcG:|cHjvMWVTUyCneIDy[ZN{cW:w MWmyOVc3QTF6MR?=
MCF-7  MlH2SpVv[3Srb36gRZN{[Xl? Mm\YNVAh|ryP NVnHdFRkOSCq M33UWolvcGmkaYTzJGlNNTF6LXXubIFv[2WmIHPlcIwhdWmpcnH0bY9v NXm0N3hiOjV5MkewNVE>
HepG2  NGXtcG1HfW6ldHnvckBCe3OjeR?= NHXvdlUyOCEQvF2= MontOUBp MU\icI9kc3NicHjvd5Bpd3K7bHH0[YQhVUGSS4OgbY5lfWOnZDDifUBmgG:pZX7veZMhXEeILd8yNS=> NFXQR4IzPTV4MES4PC=>
HepG2  M1zoT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHH5ZWQzOCEQvF2= MUOyOEBp M1LITpN2eHC{ZYPz[ZMhXEeILd8yNU1qdmS3Y3XkJINmdGxicILvcIln\XKjdHnvckBidmRiaX72ZZNqd25? MV6yOVU3ODR6OB?=
MDA-MB-231 MkPXSpVv[3Srb36gRZN{[Xl? NIjGb44zPSEQvF2= MWKyMVMhcA>? M{XGSIRm[3KnYYPld{BxNUWUS{GvNkBidmRiU{GwNGE1KGW6cILld5Nqd25? NGKwU4QzPTV3NUi3OS=>
SW480 MWLGeY5kfGmxbjDBd5NigQ>? M1LnZVIxyqEQvF2= M12xOlHDqGh? MVLy[YR2[2W|IITo[UBmgHC{ZYPzbY9vKG:oIFHUSlMheHKxdHXpci=> NETkbZUzPTR2N{ixOi=>
HCT-15 MUjGeY5kfGmxbjDBd5NigQ>? M37Vd|EhcA>? NIjjemNifHSnboXheIV{KFCJRUKtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gSZJsyqB? MnvMNlU1OzF2MkW=
HCT-15 MYfBdI9xfG:|aYOgRZN{[Xl? NHzyfnIyKGh? NGiyeINi[m:uaYPo[ZMhfGinIIDyc5Rm[3SrdnWg[YZn\WO2czDv[kBRT0V{wrDh[4FqdnO2IHP1doN2dWmwLXnu[JVk\WRiYYDvdJRwe2m| M1PuPFI2PDNzNEK1
786-O MWXBdI9xfG:|aYOgRZN{[Xl? NYnJSmFPPTEEoN88US=> MYmyOEBp MYLwc5RmdnSrYYTld:KhfGinIIDyc{1ieG:ydH;0bYMh\W[oZXP0d{Bw\iCQQx?= MnTONlQ2ODh2N{[=
A498 NYqyV3VVSXCxcITvd4l{KEG|c3H5 NYqzb2JRPTEEoN88US=> MV:yOEBp MlLqdI91\W62aXH0[ZPDqHSqZTDwdo8u[XCxcITveIlkKGWoZnXjeJMhd2ZiTlO= MYeyOFUxQDR5Nh?=
NHBE MVvGeY5kfGmxbjDBd5NigQ>? MnLYNk8zOCEQvF2= MXmyJIg> NU\1W3pW[XS2ZX71ZZRmeyCLTD2zN{B{fGmvdXzheIVlKEO[Q1y4M2lNNThic3XjdoV1cW:w MoD1NlQ1Pzl3Mk[=
A375 NVL5So5wS2WubDDJcpZie2mxbjDBd5NigQ>? M1u2ZVEx6oDVMkCgxtVO NIC5R2ozPCCq MnXwdoVlfWOnczDt[Yxidm:vYTDj[YxtKGmwdnHzbY9v MWCyOFQ3PjB|Nh?=
HBMEC NUKyWnZHTnWwY4Tpc44hSXO|YYm= NHPyVIcyOCEQvF2= M3L4SVEhcA>? M1nifoJtd2OtczDWSWdHNWmwZIXj[YQhTXCqQUKg[ZhxemW|c3nvci=> NF63[2ozPDR3OEm4Ni=>
HPAEpiCs  NVzzd|RITnWwY4Tpc44hSXO|YYm= NH62XZE{OCEQvF2= MUexJIg> MXrpcohq[mm2czDUUmYu|rFic4TpcZVt[XSnZDDwOFIweDR2IF3BVGsheGixc4Doc5J6dGG2aX;u NG[yb2QzPDR2MUi3NC=>
BeWo NYfoemV5TnWwY4Tpc44hSXO|YYm= NYrlbm9bOTEEoN88US=> NIryNJEzKGh? NYPhXFFWcW6qaXLpeJMhTVKNMT:y MX6yOFQ{Ozh2Nh?=
PC3  NVz4eJRmSXCxcITvd4l{KEG|c3H5 NUnUfGZjPTBizszN NWPjV3d2OC53IHi= NIfiOnBqdmirYnn0d{BOUFlvNES5MYlv\HWlZXSgZZBweHSxc3nzxsA> M1PMNVI1PDJ2OEi5
HGC-27 M2rVeGFxd3C2b4Ppd{BCe3OjeR?= MoDoNUDDvU1? NYXxbWt3OSCq NUPOWm5ne3WycILld5NmeyCUQVSwNFEheGy3czDNT{0zOjB4LXnu[JVk\WRiY3XscEB3cWGkaXzpeJkhdG:|cx?= NV;KblNSOjR2MU[zOFk>
MCF-7 MUHGeY5kfGmxbjDBd5NigQ>? NWjvUVlmOTEEoN88US=> M1zXeVExNzNyIH3pci=> MWry[YR2[2W|IITo[UBWXFBvZHXw[Y5l\W62IFXST{BxcG:|cHjvdplt[XSrb36= NYjPPYNTOjR|OUC4NVk>
HUVECs NX7meIp1TnWwY4Tpc44hSXO|YYm= MXOxNOKh|ryP Mn:2NUBp NF7sSFZqdmirYnn0d{B1cGViSFTMJJJm\HWlZXSgR29ZNTJiZYjwdoV{e2mxbjDhcoQhWEeLLUKgdoVt\WG|ZR?= Mlq0NlQ{QDVzMEm=
HeLa M2LFWmZ2dmO2aX;uJGF{e2G7 Ml3QOVAh|ryP M3jQcFAvPSCq MmrkZoxw[2u|IGTSXE0yKG63Y3zlZZIhdWmpcnH0bY9vKGGwZDDUXG5KWCCmb4fuMZJm\3WuYYTpc44> NHHHPYMzPDN5NkiyOy=>
HL-60  M{PkeGZ2dmO2aX;uJGF{e2G7 NEO3bXIyOC9{MDFOwG0> NXzEO2FSOSCq MUfpcohq[mm2czD0bIXDqE5wIHPobY5mdnOrc3X4eJJi[3UEoHnu[JVk\WRiZHnm[oVz\W62aXH0bY9vKGmwdH:g[5JidnWub3P5eIV{ MX6yOFM2PzB{MB?=
HL-60 MXnGeY5kfGmxbjDBd5NigQ>? MnroNkDDvU1? MoH5NVYhcA>? MV\EUXNQ Mm\kbY5pcWKrdIOgeIhmKGG|c3;jbYF1cW:wIH;mJJBUPjJzIGLh[k0yKGGwZDDOSmFV[zNuIHHu[EB1cGViUlGtbY5lfWOnZDDwbI9{eGixconsZZRqd25ib3[gcpVkdGWjcjDOSmFV[zN? M1;q[FI1OzNyME[4
HEK 293 MmTkSpVv[3Srb36gRZN{[Xl? M4G2UVExKM7:TR?= NITpZ3A2KGh? MUPEUXNQ MYTpcohq[mm2czDXcpQucW6mdXPl[EDPui2lYYTlcolvN1SFRkSgZYN1cX[rdImgZY5lKG63Y3zlZZIh|rJvY3H0[Y5qdiCjY3P1cZVt[XSrb36= MUeyOFMzPDN4Nh?=
HEK 293 NUPIbYNjTnWwY4Tpc44hSXO|YYm= MX:xNEDPxE1? NGXHfIE2KGh? NWjEc282TE2VTx?= MWfzeZBxemW|c3XzJJRp\SCFUmSgZYN1cX[rdIm= NI\Wb|IzPDN{NEO2Oi=>
SW480 MY\GeY5kfGmxbjDBd5NigQ>? NEDi[oQyOCEQvF2= NXX0SYZlOjBiaB?= MnTJSG1UVw>? M{\kV5N2eHC{ZYPz[ZMhfGinIFPSWEBi[3Srdnn0fS=> MkDoNlQ{OjR|Nk[=
HCSMCs MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWKxNEDPxE1? MVWyOEBp M4OzN4Jtd2OtczDGRWJRPC2rbnT1Z4VlKEiFQWPNR{Bxem:uaX\ldoF1cW:w M4HXXVI1OzF{M{ix
PANC-1 NISwOlVHfW6ldHnvckBCe3OjeR?= NV7WcGVEOjBizszN NGjKOpk1QCCq M13YcIlvcGmkaYTzJJRp\SCneIDy[ZN{cW:wIH;mJO6VPkRiaX6gdoV{eG:wc3WgeI8hfGinIGDQRXLPvMLiYXfvcol{fMLi MYqyOFI6PDF|Mx?=
A549 MkfqSpVv[3Srb36gRZN{[Xl? MlPPN|Ah|ryP NHjSWYQxNjViaB?= MVfEUXNQ M2\uPYlvcGmkaYTzJJRp\SC2aILvcYJqdi2rbnT1Z4VlKEmOLUivR3hEVDhvTIXjJIFkfGm4aYT5 NHSxWIszPDJ5N{[5Oi=>
A549 NIWwW5FHfW6ldHnvckBCe3OjeR?= NEHRNHQ{OCEQvF2= M4H0NFAvPSCq NWPQcXRmTE2VTx?= NFO1dGFqdmirYnn0d{B1cHKxbXLpck1qdmS3Y3XkJGMwTUKSzsKgWIhzOjN3wrDwbI9{eGixconsZZRqd25? NWW4V2FWOjR{N{e2PVY>
MC-3 MnntRZBweHSxc3nzJGF{e2G7 NH3OUnYyOCEQvF2= NHPz[|EzPCCq MVvwc5RmdnSrYYTl[EBOTVOFLXnu[JVk\WRiYYDvdJRwe2m|IHnuJEBk\Wyucx?= Mkj2NlQzPzB3MkO=
Raji  M1zV[mZ2dmO2aX;uJGF{e2G7 MUWxNEDPxE1? M1naWlEhcA>? M{PMPIJtd2OtczDod2JCTkZiaX7keYNm\CCHcnuxM|IheGixc4Doc5J6dGG2aX;u MYKyOFI3QTZ|MB?=
Raji  NEDocYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY[xNEDPxE1? NVnNW3NkOSCq NEHYT5FqdmirYnn0d{B1cGViYnHzZYwhd3JiaIPCRWZHNXO2aX31cIF1\WRiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJk> MX6yOFI3QTZ|MB?=
HT29 NIHmbGFHfW6ldHnvckBCe3OjeR?= NF3HclEyOCEQvF2= NULwVGFTOiCq M1qyWYlvcGmkaYTzJI9nKEqDS{KsJGVTUzFxMjDhcoQhW1SDVEOgdIhwe3Cqb4L5cIF1cW:w Mmr2NlQzPjV{OUO=
HepG2 M17ROWFxd3C2b4Ppd{BCe3OjeR?= NX\0SHpbOjBizszN M1TjfFI1KGh? MWXpcohq[mm2czDFVmsyNzJicHjvd5Bpd3K7bHH0bY9vKGGwZDDlcohidmOnczDWRlEucW6mdXPl[EBieG:ydH;zbZM> NUjJ[mJtOjR{NEe5NFk>
HepG2 NF7ydXhHfW6ldHnvckBCe3OjeR?= NV7sVIhlOjBizszN MVKyJIg> M1\vT4VvcGGwY3XzJHZDOS2rbnT1Z4VlKE[RWF:zZUB1emGwc3PybZB1cW:wYXygZYN1cX[rdIm= NXrXe3hyOjR{NEe5NFk>
TE4 NFr1NYhHfW6ldHnvckBCe3OjeR?= NHjvTIszOC93MD:xNFAh|ryP MVW0PEBp M37FUGROW09? NIXLSIpqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MknHNlQzPDRyMkO=
TE1 MYPGeY5kfGmxbjDBd5NigQ>? MUCyNE82OC9zMECg{txO Mn7DOFghcA>? NHnkXYtFVVOR NFG0fGxqdmirYnn0d{BxNUW{azDhcoQhf2:{dH3hco5qdiCmb4fudoVofWyjdHXkJJAuSWu2IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4r6NFI1OjR2MEKz
KYSE30 M1XQT2Z2dmO2aX;uJGF{e2G7 NGq5W44zOC93MD:xNFAh|ryP NXfEbnVLPDhiaB?= MXjEUXNQ MX3pcohq[mm2czDwMWVzcyCjbnSge49zfG2jbn7pckBld3ewcnXneYxifGWmIICtRYt1KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUD0PJQ{OjR{NESwNlM>
TE1 NFzW[HZHfW6ldHnvckBCe3OjeR?= M2fCN|UxKM7:TR?= MVG0PEBp NIL3S4lFVVOR MmrReZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MmrBNlQzPDRyMkO=
TE3 NIPXWIJHfW6ldHnvckBCe3OjeR?= MXi1NEDPxE1? M4DLWVQ5KGh? MmXkSG1UVw>? NYXVUXFTfXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= NFL0eY0zPDJ2NECyNy=>
TE4 MmjBSpVv[3Srb36gRZN{[Xl? NXja[G52PTBizszN M3XtZlQ5KGh? NFX6S4hFVVOR MkDzeZBz\We3bHH0[ZMhfGinIHX4dJJme3Orb36gc4YhUEyDIHPsZZN{KEl? MmXYNlQzPDRyMkO=
TE5 MW\GeY5kfGmxbjDBd5NigQ>? NFPrb3g2OCEQvF2= MVi0PEBp M4PscmROW09? NFPBOpZ2eHKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKTFGgZ4xie3NiSR?= MVyyOFI1PDB{Mx?=
KYSE30 M1jXS2Z2dmO2aX;uJGF{e2G7 NFTp[Xg2OCEQvF2= M{PnT|Q5KGh? NF7JbllFVVOR NVvzWmt4fXC{ZXf1cIF1\XNidHjlJIV5eHKnc4Ppc44hd2ZiSFzBJINt[XO|IFm= M13V[|I1OjR2MEKz
MKN7 NGfKSYJHfW6ldHnvckBCe3OjeR?= MWi1NEDPxE1? NUP1OFNTPDhiaB?= M1LPXGROW09? MU\pcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| NFfPdo4zPDJ2NECyNy=>
OE19 M2jkZmZ2dmO2aX;uJGF{e2G7 MYK1NEDPxE1? NYDae5RlPDhiaB?= MV7EUXNQ NYfSeG1icW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MoLzNlQzPDRyMkO=
KATOIII  NUXw[Hp{TnWwY4Tpc44hSXO|YYm= Mme2OVAh|ryP NF7BdGM1QCCq MoGxSG1UVw>? NXjYPVhEcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> MoDjNlQzPDRyMkO=
NCI-N87  NHPCblhHfW6ldHnvckBCe3OjeR?= M1zy[lUxKM7:TR?= NUnFN5dyPDhiaB?= MoPvSG1UVw>? MVfpcoNz\WG|ZYOg[ZhxemW|c3nvckBw\iCKTFGtRVAzKG:{IFjMRU1COjRibX;s[YN2dGW| NWK3PFVYOjR{NESwNlM>
NUGC3 MYXGeY5kfGmxbjDBd5NigQ>? MoXkOVAh|ryP NFHOeYU1QCCq NWexfIJtTE2VTx?= NIflTm9qdmO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDIUGEuSTB{IH;yJGhNSS2DMkSgcY9t\WO3bHXz MoLFNlQzPDRyMkO=
NUGC2 NYXvSFBGTnWwY4Tpc44hSXO|YYm= NHj0dmQ2OCEQvF2= MWG0PEBp NXG5O|M2TE2VTx?= NXjxZlFQcW6lcnXhd4V{KGW6cILld5Nqd25ib3[gTGxCNUFyMjDvdkBJVEFvQUK0JI1wdGWldXzldy=> NYXEWI1jOjR{NESwNlM>
SGC-7901  M3Hpd2Fxd3C2b4Ppd{BCe3OjeR?= MWiyNEDPxE1? M17FOFI1KGh? MVfpcohq[mm2czDDVE1u\WSrYYTl[EBieG:ydH;zbZM> M3LEXlI1OjRzM{Wx
MG-63 M3\lcmZ2dmO2aX;uJGF{e2G7 NEezfYczOCEQvF2= Mn:4NE42KGh? NWLHWHJM[myxY3vzJJRp\SCFSD3pcoR2[2WmIIDoc5NxcG:{eXzheIVlKEWOS{GgdJJwfGWrbjDlfJBz\XO|aX;u MmL4NlQzOzl4NEC=
ARPE-19 M4riR2Z2dmO2aX;uJGF{e2G7 MUWyNEDPxE1? M1W3SFAvPSCq M3zSOIlvcGmkaYTzJGFx\Wyrbj3pcoR2[2WmIIDoc5NxcG:{eXzheIlwdiCxZjDFdosh[W6mIFHreC=> NHTGTXozPDJ{N{mxPC=>
CRL-2302 NHfLNYpHfW6ldHnvckBCe3OjeR?= MYWyNEDPxE1? NWfGZpR2OC53IHi= MkXrbY5pcWKrdIOgRZBmdGmwLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIFXyb{BidmRiQXv0 NIDrPG0zPDJ{N{mxPC=>
MCF-7 NHPFXmpHfW6ldHnvckBCe3OjeR?= NVjXbWo{OjBizszN NV7Ofm5lOSCq MmDLZYJwdGm|aHXzJIV5eHKnc4Ppc44hd2ZicHjvd5Bpd3K7bHH0[YQhTVKNIHPvMZRz\WG2bXXueEB4cXSqIHPvcop2\2G2ZR?= MXeyOFIyPjJ6OR?=
MCF-7 MYDBdI9xfG:|aYOgRZN{[Xl? NHjjUHEzOCEQvF2= M3HVWFEhcA>? NGTib2JqdmO{ZXHz[ZMh[2G|cHHz[U06KGWweont[UBi[3Srdnn0fS=> MnS4NlQzOTZ{OEm=
DLD-1  M3LicWZ2dmO2aX;uJGF{e2G7 MlzINlDDqM7:TR?= NILvclQ1QCCq NYWwSlhPemWmdXPld{B1cGViQl7JVFMh\XiycnXzd4lwdiCycnWteJJm[XSnZDD3bZRpKDVvYYrhMYRE MnjUNlQzOTF3OEG=
HT-29 NFfUfGdHfW6ldHnvckBCe3OjeR?= MlfmNlDDqM7:TR?= NGfIXpU1QCCq NGfZRYVz\WS3Y3XzJJRp\SCETlnQN{BmgHC{ZYPzbY9vKHC{ZT30doVifGWmIIfpeIghPS2jenGt[GM> MnLMNlQzOTF3OEG=
7402 NXLMPYIxSXCxcITvd4l{KEG|c3H5 NVWwbGxWOzBizszN MYS1JIQ> NGr1S2hl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v Mmq3NlQzOTF{NUO=
7721 NGrTXpFCeG:ydH;zbZMhSXO|YYm= NX\Bd5dzOzBizszN MmDiOUBl Mn;i[IVkemWjc3XzJINmdGxicILvcIln\XKjdHnvci=> M3HNVVI1OjFzMkWz
SGC7901  MXLBdI9xfG:|aYOgRZN{[Xl? MYi1NOKh|ryP NYP5b5FIOjRxNEivO|IhcA>? NWHlO|NLTE2VTx?= NVfrSIg1cW6mdXPld{BieG:ydH;zbZMh[2:vYnnu[YQhf2m2aDDKRWszKHOqUl7B MknnNlQyPzh{NEC=
SMMC7721 NHTPcI5HfW6ldHnvckBCe3OjeR?= MYeyOU82OCEQvF2= M{L4W|I1KGh? M4PneZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YheC2Da4Sgc5IheC2HUluxM|LDqA>? MXuyOFE3QDB3Nh?=
MCF-7 NVvmOYpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLFNVAh|ryP NWW3OIhuPDiq MVnEUXNQ MV3y[ZZmenOnczDCUmYucW6mdXPl[EBk\WyuIHP5Z4xmKGG{cnXzeC=> NGLNW|AzPDF4M{SwOC=>
Caco-2 NGT4bmxHfW6ldHnvckBCe3OjeR?= MXe1NOKh|ryP NVHKToNoPDiq MXHEUXNQ MYrlcohidmOnczD0bIUhdVKQQTDs[ZZmdHNib3dCpHNEVk5zQTzGXHlFOy{EoFzDWEzDqEyRWD|CpGhKTjODLNMgXmcyPi{EoGDESVZCyqCjbnVCpGxISUyVMUdCpIdmdmW|wrDjc{11emWjdHXkJJdqfGhiRHX4 NEjxSYEzPDF4MU[5OS=>
HAECs MVvGeY5kfGmxbjDBd5NigQ>? NUnZdZdJOTBizszN NEjCWIsyKGh? MX|CpIF1fGWwdXH0[ZMhXE6ILd8xMZN1cW23bHH0[YQhUUODTT2xJIFv\CCYQ1HNMVEh\XiycnXzd4lwdg>? MV[yOFE{PDZ3Nx?=
Ca9-22 MV;GeY5kfGmxbjDBd5NigQ>? NWT2UGNMOyEQvF2= NIXSdlMyKGh? MWPhZo9tcXOqZYOgeIhmKGGkaXzpeJkhd2ZiSHLSJJRwKGmwZIXj[UBKVC16IIDyc4R2[3Srb36= NETPRlIzPDF{NkWzNi=>
Ca9-22 MUTGeY5kfGmxbjDBd5NigQ>? M2DkXlMh|ryP MWqxM|IhcA>? NYHqSlNCemWmdXPld{BJ[lJvaX7keYNm\CCDVF[tNkBxcG:|cHjvdplt[XSrb36= MonTNlQyOjZ3M{K=
AGS MVLGeY5kfGmxbjDBd5NigQ>? M3[yXlExKM7:TdMg NHvOS2gxNjViaB?= M2LPT4lvcGmkaYTzJJRp\SC3cILl[5Vt[XSrb36gc4YhfGinIFnMMVgh\2WwZR?= M3PBdlI1OTB4MU[2
Caco-2  M1fnOWFxd3C2b4Ppd{BCe3OjeR?= MWWxNOKh|ryP NG\nWWUzPMLiaB?= NHOzeYFl\WO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUA2NU[X MX:yOFA6PTh4Mx?=
HCT-8 M1XxcWFxd3C2b4Ppd{BCe3OjeR?= M4TDVlExyqEQvF2= MUiyOOKhcA>? NHHUO|dl\WO{ZXHz[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUA2NU[X NG\lXJIzPDB7NUi2Ny=>
A549 MWTGeY5kfGmxbjDBd5NigQ>? MnyyOVDDqM7:TR?= NYHGcpluOiCq M4TBV4Jtd2OtczDFVmsheGixc4Doc5J6dGG2aX;uJI1m\GmjdHXkJIJ6KDFuMj3OVS=> NEezOowzPDB4N{eyOy=>
HPMC NV7Pd3pOTnWwY4Tpc44hSXO|YYm= NUTYR3dNOTEEoN88US=> M{HoNVQ5KGh? MnrZdoV3\XK|ZYOgeIhmKGOqYX7n[ZMhcW5iY3XscEBud3KyaH;sc4d6KGmwZIXj[YQh[nliSFfQSHM> NHjj[YozPDB2MkizPC=>
HPMC MYjBdI9xfG:|aYOgRZN{[Xl? NVzPNIpxOTEEoN88US=> M4nzeVI1yqCq M4fvPZJmfmW{c3XzJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlv\HWlZXSgZpkhUEeSRGO= M{[1c|I1ODR{OEO4
MGC803  NEfVUIxCeG:ydH;zbZMhSXO|YYm= NXzIWmliOjEEoN88US=> NFLGSoQyKGh? NHvyPJpqdmirYnn0d{BieG:ydH;zbZMhcW6mdXPl[EBjgSCLRl6t{tHDqGGwZDC15qCzNUSIVWK= MoGyNlQxOjd5NUC=
SGC7901 MlfkRZBweHSxc3nzJGF{e2G7 M1rRWFIxyqEQvF2= Mn\6NUBp M4Pxc4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KEmITj5OteKh[W6mIEZihNIuTE[XUh?= MmHVNlQxOjd5NUC=
COLO205 NUDGTFRGSXCxcITvd4l{KEG|c3H5 NGD1OVkyOC9{MD:0NEDPxE1? MoXXNlQhcA>? MX;pcoR2[2W|IFTORUBt[WSmZYKg[o9zdWG2aX;u M3PmUVI1ODF7MUC4
G292  MXnBdI9xfG:|aYOgRZN{[Xl? NF6zc4U{OMLizszN NH3RXIgzKGh? Mn76doV{fG:{ZYOgZ4Fxe2GrY3nuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MWSyOFAyOjl|MB?=
BxPC-3 Mn;ESpVv[3Srb36gRZN{[Xl? MUKxNEDPxE4EoB?= MYS2JIg> M1ztc4lv[3KnYYPlJI1qWi1zNEOg[ZhxemW|c3nvci=> M4Xl[|I{QTd|N{Gw
HPAF-II M1vTWGZ2dmO2aX;uJGF{e2G7 MYKxNEDPxE4EoB?= NUnoUnczPiCq MlvtbY5kemWjc3WgcYlTNTF2MzDlfJBz\XO|aX;u M2nOZlI{QTd|N{Gw
HL-60 NF;5cIZCeG:ydH;zbZMhSXO|YYm= M3[2UFUxyqEQvF2= M2K4flEhcA>? NWrWRmQyemW|Y4Xld{BDSTF2NTDt[YRq[XSnZDDhdI9xfG:|aYO= MXyyN|k1QDd3MR?=
HepG2 M{i2bGZ2dmO2aX;uJGF{e2G7 MYK0NEDPxE1? MV:2M|EzKGh? NHvIVZVqdmirYnn0d{B1cGViaX7jdoVie2Vib3[gdE1GWktzIHHu[EBxNWNvSoXuJJBzd3SnaX6g[ZhxemW|c3nvckBjgSCSTB?= MW[yN|k1Ojh3MR?=
HUVECs MnrvSpVv[3Srb36gRZN{[Xl? NUnjSVhJOjVizszN NYLBdop[OSCq MV;pcoNz\WG|ZTDOSk3PwkJicE[1JI52[2ynYYKgeJJidnOub3PheIlwdg>? NI\GSVIzOzlyMUCwPC=>
LNCaP  M33qSGZ2dmO2aX;uJGF{e2G7 M1\0cFExKM7:TdMg MWGxJIg> NWPuRXpn\GWlcnXhd4V{KHSqZTDFS2YhfXC{ZXf1cIF1\WRicD3ZRk0y NEDaXWUzOzh|OEOxPC=>
HL60  MnXSSpVv[3Srb36gRZN{[Xl? NH;BT2EzOMLizszN M2TPWFczKGh? MkniSG1UVw>? MlrTbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= M2TucVI{QDJ3NUi1
NB4  NEK4eohHfW6ldHnvckBCe3OjeR?= NULROpFpOTBizszNxsA> NHz1S5U4OiCq NFLqZ|RFVVOR MlTDbY5pcWKrdIOg[IF{[XSrbnniMYlv\HWlZXSgR2QyOWJiZYjwdoV{e2mxbh?= MXGyN|gzPTV6NR?=
EPOR/CR3 NIT0eYRHfW6ldHnvckBCe3OjeR?= NETye4E2OMLizszN M4\Q[|MhcA>? MWfy[YR2[2W|IFXQU{BidmRxb4KgTWwuOy2rbnT1Z4VlKHSqZTD0fZJwe2mwZTDwbI9{eGixconsZZRqd28EoB?= NE\aUFczOzh{MEezNS=>
HUASMCs MkjYSpVv[3Srb36gRZN{[Xl? MkOxNVAh|ryPwrC= MVeyOEBp NVHaPGdV\GmvaX7pd4hmeyCDbnegTWku[2G3c3XkJHNQS1N|IH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbtMg NGDEdm4zOzhzNkS2PC=>
HUASMCs NU\1N|h5TnWwY4Tpc44hSXO|YYm= MkDhNVAh|ryPwrC= NELVOoIzPCCq NYTiSo4xcW6qaXLpeJMhSW6pIFnJMYlv\HWlZXSgSXJMOS9{IIDoc5NxcG:{eXzheIlwdiCuZY\lcC=> NIW3cIEzOzhzNkS2PC=>
SGC7901 MUjGeY5kfGmxbjDBd5NigQ>? M4jxeVExKM7:TdMg NXjwU29ZOjRiaB?= MlLXbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRWLLNU8z MlrvNlM4QTJ3OEi=
MKN45 MVTGeY5kfGmxbjDBd5NigQ>? MmDoNVAh|ryPwrC= M1uzNlI1KGh? MXXpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwbI9{eGixconsZZRm\CCHUluxM|I> NXP1e3NCOjN5OUK1PFg>
SGC7901 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHUfpMyOCEQvF5CpC=> NW\HTI1oOjRxNEivO|IhcA>? NILJNnhqdmirYnn0d{Bk\WyuIHfyc5d1cCClbz30doVifGWmIIfpeIghTEGSVB?= M1fuSVI{Pzl{NUi4
MKN45 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjFSlI1OTBizszNxsA> MnzPNlQwPDhxN{KgbC=> M2HmSolvcGmkaYTzJINmdGxiZ4Lve5RpKGOxLYTy[YF1\WRid3n0bEBFSVCW NFvLUZczOzd7MkW4PC=>
SGC7901 Mnj2RZBweHSxc3nzJGF{e2G7 Ml6xNVAh|ryPwrC= MnHoNlQhcA>? NYDRc5JxcW6lcnXhd4V{KHSqZTDERXBVNWmwZIXj[YQh[2WubDDhdI9xfG:|aYO= NGO4V4IzOzd7MkW4PC=>
MKN45 MXLBdI9xfG:|aYOgRZN{[Xl? NHPIdmIyOCEQvF5CpC=> NHTmO|EzPCCq M3P1UYlv[3KnYYPld{B1cGViRFHQWE1qdmS3Y3XkJINmdGxiYYDvdJRwe2m| MmnLNlM4QTJ3OEi=
BxPC-3 cells NXzaU2NWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTwXJFjOjEEoN88US=> NHraVm0xNjViaB?= NWjZcGJbcW6qaXLpeJMhXkWJRj3BMZJm\3WuYYTl[EBJXV[HQzDndo94fGhiYX7kJJR2[mViZn;ycYF1cW:wIHnu[JVk\WRiYomgVGFTNTJiQWC= MlyyNlM4PjRyNE[=
NB4  Mnm1RZBweHSxc3nzJGF{e2G7 MmrHNVAwOjBxNkCg{txO MYCxMlUhcA>? M4fTV2ROW09? M{WxfoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDjc{11emWjdHXkJJdqfGhiUHHjcIl1[XinbB?= M1fNeFI{PzN3NUSx
HepG2  NF7IW3FHfW6ldHnvckBCe3OjeR?= MlLPNlDDqM7:TR?= MV6yOEBp MoXqbY5pcWKrdIOgeIhmKEiRLUGgdJJwfGWrbjDlfJBz\XO|aX;uJINwNXS{ZXH0[YQhf2m2aDDt[ZRnd3KvaX6= MXOyN|cxPzZyOR?=
HUVECs M1HvNGFxd3C2b4Ppd{BCe3OjeR?= NWHzN|FrOi92IN88US=> NWjuSnhROjRxNEigbC=> NWD6R29DcW6mdXPld{Bk\WyuIHTlZZRp MX[yN|cxPzV{MB?=
KG-1  MUjBdI9xfG:|aYOgRZN{[Xl? NYPXWmNnOjEEoN88US=> M4rXcFEzKGh? M{nHPIVvcGGwY3XzJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomgV|E> MU[yN|cxPjZ7MR?=
AML 1# M2XrOGFxd3C2b4Ppd{BCe3OjeR?= MXGyNOKh|ryP Mnr3NVIhcA>? NV[0bIFJ\W6qYX7j[ZMh[2WubDDhdI9xfG:|aYOgbY5lfWOnZDDifUBUOQ>? NVu4bnBKOjN5ME[2PVE>
A2780  MmfzSpVv[3Srb36gRZN{[Xl? NWDndJNDOjEEoN88US=> M2fGUVEhcA>? MnG3Zoxw[2u|IFTUR2QucW6mdXPl[EBFWjViZYjwdoV{e2mxbh?= NF7xZ4YzOzZ7Nki2Ni=>

... Click to View More Cell Line Experimental Data

In vivo Treatment of mice 30 minutes before focal cerebral ischemia with PD98059 protects against damage, resulting in a decrease in infarct volume. [5] Pretreated with PD98059 (10 mg/kg per i.v. injection) 30 minutes before and then together with hourly cerulein injections for 3 hours significantly ameliorates cerulein-induced acute pancreatitis ipancreatitis on the basis of pancreatic wet weight and histology. [6] Administration of PD98059 (10 mg/kg) in mice 1 hour after carrageenan causes a reduction in all the parameters of inflammation measured. [7]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro MEK-inhibitory activity:

Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50 μL of 50 mM Tris, pH 7.4/10 mM MgCl2/2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE.
Cell Research:

[1]

+ Expand
  • Cell lines: K-Balb, KNRK, v-raf-3Y1, SRA/3Y1, EGFR/3T3, and K562
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 3 dyas, or 7-10 days
  • Method:

    For monolayer growth, cells are plated into multi-well plates at 10,000-20,000/mL. Forty-eight hours later, various concentrations of PD98059 are added to the cell growth medium and incubation is continued for an additional 3 days. Cells are then removed from the wells by incubation with trypsin and enumerated with a Coulter Counter. For growth in soft agar, cells are seeded into 35-mm dishes at 5,000-10,000 cells per dish with growth medium containing 0.3% agar and desired concentrations of PD98059. After 7-10 days of growth, visible colonies are manually enumerated with the aid of a dissecting microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male Sprague–Dawley rats with acute pancreatitis
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: 10 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (52.37 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
1mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 267.28
Formula

C16H13NO3

CAS No. 167869-21-8
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to formulate this inhibitor for i.p. injection?

  • Answer:

    You can prepare the stock by the vehicle 30% PEG400/0.5% Tween80/5% Propylene glycol, 0.5% CMC.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products4

Tags: buy PD98059 | PD98059 supplier | purchase PD98059 | PD98059 cost | PD98059 manufacturer | order PD98059 | PD98059 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID